Congenital heart disease and incremental risks of COVID-19 1 | INTRODUCTION Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first reported in the city of Wuhan, China in 2019, before spreading globally in the following months and causing a pandemic. 1 According to the World Health Organization, as of October 30, 2020, there have been 44,888,869 confirmed cases and 1,178,475 confirmed deaths due to COVID-19. 2 Patients with COVID-19 can have a range of different presentations including a fever, headaches, dry cough, fatigue, ageusia, and anosmia. 3,4 Angiotensin-converting enzyme 2 (ACE2) is an enzyme that is expressed in the heart, kidneys, intestines, arteries, and most importantly the respiratory tract epithelium. It has been confirmed as the entry point for SARS-CoV-2 into host cells. 5 Studies have suggested that it downregulates ACE2 and causes angiotensin-II levels to accumulate, whose harmful effects can lead to acute respiratory distress syndrome (ARDS). 6,7 COVID-19 has been shown to potentially lead to complications in different organ systems in the human body, including the renal and cardiovascular systems (CVSs). 3 In the CVS, these complications include heart failure and arrhythmia. 4